UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Volltextzugriff (PDF)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays

Scientific reports, 2019-01, Vol.9 (1), p.114-114, Article 114

2019

Volltextzugriff (PDF)

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

European urology, 2023-01, Vol.83 (1), p.15-26

2023

Volltextzugriff (PDF)

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Cancer Immunology, Immunotherapy, 2013-01, Vol.62 (1), p.137-147

2013

Volltextzugriff (PDF)

Signaling Through OX40 Enhances Antitumor Immunity

Seminars in oncology, 2010-10, Vol.37 (5), p.524-532

2010

Volltextzugriff (PDF)

Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines

Journal of translational medicine, 2007-11, Vol.5 (1), p.56-56, Article 56

2007

Volltextzugriff (PDF)

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

European urology oncology, 2024-06, Vol.7 (3), p.509-518

2024

Volltextzugriff (PDF)

Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts

European journal of immunology, 2009-11, Vol.39 (11), p.3121-3133

2009

Volltextzugriff (PDF)

Development of antitumor immune responses in reconstituted lymphopenic hosts

Cancer research (Chicago, Ill.), 2002-07, Vol.62 (14), p.3914-3919

2002

Volltextzugriff (PDF)

Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity

The Journal of immunology (1950), 2009-09, Vol.183 (6), p.3682-3689

2009

Volltextzugriff (PDF)

Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor

Journal of translational medicine, 2007-03, Vol.5 (1), p.14-14, Article 14

2007

Volltextzugriff (PDF)

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects

Current molecular medicine, 2009-08, Vol.9 (6), p.673

2009

Volltextzugriff (PDF)

TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells

The Journal of immunology (1950), 2003-02, Vol.170 (4), p.2004-2013

2003

Volltextzugriff (PDF)

Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein

Journal of immunotherapy, 2008-01, Vol.31 (1), p.43-51

2008

Volltextzugriff (PDF)

Tumour‐induced polarization of tumour vaccine‐draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies

Immunology, 2003-03, Vol.108 (3), p.409-419

2003

Volltextzugriff (PDF)

Immunotherapy for melanoma: the good, the bad, and the future

Current oncology reports, 2005-09, Vol.7 (5), p.383-392

2005

Volltextzugriff (PDF)

Depletion of tumor-induced regulatory T cells prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts

European journal of immunology, 2009-11, Vol.39 (11), p.3121-3133

2009

Volltextzugriff (PDF)

Increased lymphopenia results in higher percentages of FoxP3+ T cells in patients reconstituted by PBMC adoptive transfer and vaccinated (41.36)

The Journal of immunology (1950), 2009-04, Vol.182 (1_Supplement), p.41-41.36

2009

Volltextzugriff (PDF)

Signaling through OX40 Enhances Anti-tumor Immunity

Seminars in oncology, 2010-10, Vol.37 (5), p.524-532

2010

Volltextzugriff (PDF)

Signaling Through OX40 Enhances Antitumor Immunity : Immunologic checkpoints for cancer treatment: from scientific rationale to clinical application

Seminars in oncology, 2010, Vol.37 (5), p.524-532

2010

Volltextzugriff (PDF)

Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile prodicts inherent strong immunogenicity of the tumour and

Immunology, 2003-03, Vol.108 (3), p.409

2003

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(12)
Animals
(10)
Mice
(9)
Female
(7)
Male
(7)
Mice, Knockout
(7)
Oncology
(7)
Immunology
(6)
Immunotherapy
(6)
Mice, Inbred C57bl
(6)
T-Lymphocytes, Regulatory - Immunology
(5)
Aged
(4)
Cancer Vaccines - Immunology
(4)
Medicine, Research & Experimental
(4)
Melanoma, Experimental - Immunology
(4)
Neoplasms - Immunology
(4)
Pembrolizumab
(4)
Prostatic Neoplasms, Castration-Resistant - Pathology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26]

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Signaling Through OX40 Enhances Antitumor Immunity

Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts

Development of antitumor immune responses in reconstituted lymphopenic hosts

Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity

Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects

TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells

Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein

Tumour‐induced polarization of tumour vaccine‐draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies

Immunotherapy for melanoma: the good, the bad, and the future

Depletion of tumor-induced regulatory T cells prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts

Increased lymphopenia results in higher percentages of FoxP3+ T cells in patients reconstituted by PBMC adoptive transfer and vaccinated (41.36)

Signaling through OX40 Enhances Anti-tumor Immunity

Signaling Through OX40 Enhances Antitumor Immunity : Immunologic checkpoints for cancer treatment: from scientific rationale to clinical application

Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile prodicts inherent strong immunogenicity of the tumour and

Suchergebnisse filtern